Navigation Links
Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model
Date:8/22/2010

Tampa, FL (August 23, 2010) -- A signaling protein released during rheumatoid arthritis dramatically reduced Alzheimer's disease pathology and reversed the memory impairment of mice bred to develop symptoms of the neurodegenerative disease, a new study by the University of South Florida reports. Researchers found that the protein, GM-CSF, likely stimulates the body's natural scavenger cells to attack and remove Alzheimer's amyloid deposits in the brain.

The study appears online today in the Journal of Alzheimer's Disease.

People with rheumatoid arthritis, a chronic disease leading to inflammation of joints and surrounding tissue, are less likely than those without arthritis to develop Alzheimer's. While it was commonly assumed that non-steroidal anti-inflammatory drugs may help prevent onset and progression of Alzheimer's disease, recent NSAID clinical trials proved unsuccessful for patients with Alzheimer's.

The USF researchers are among the first to look at what effect innate immunity gone awry in rheumatoid arthritis may play in protecting against Alzheimer's disease.

"Our findings provide a compelling explanation for why rheumatoid arthritis is a negative risk factor for Alzheimer's disease," said principal investigator Huntington Potter, PhD, professor of molecular medicine at the USF Health Byrd Alzheimer's Institute and director of the Florida Alzheimer's Disease Research Center.

"Moreover, the recombinant human form of GM-CSF (Leukine) is already approved by the FDA and has been used for years to treat certain cancer patients who need to generate more immune cells," Dr. Potter said. "Our study, along with the drug's track record for safety, suggests Leukine should be tested in humans as a potential treatment for Alzheimer's disease."

The researchers analyzed three rheumatoid arthritis growth factors in mouse models and identified the signaling protein GM-CSF as the most promising fo
'/>"/>

Contact: Anne DeLotto Baier
abaier@health.usf.edu
813-974-3300
University of South Florida (USF Health)
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. New way of classifying rheumatoid arthritis aimed at identifying the disease earlier
2. Could Drinking Help Thwart Rheumatoid Arthritis?
3. Majority of Ontarians suffering from rheumatoid arthritis not receiving needed speciality care
4. New Approach to Rheumatoid Arthritis
5. Sex lives of patients are negatively affected by rheumatoid arthritis and SLE
6. Women who consume large amounts of tea have increased risk of rheumatoid arthritis
7. Partners grieve rheumatoid arthritis diagnosis as much as patients
8. Stomach Bacteria Might Trigger Rheumatoid Arthritis
9. Almost three quarters of women with rheumatoid arthritis worldwide suffer pain daily
10. Shoulder arthritis? What patients need to know before treatment
11. Knee arthritis? Flexible options can help keep you active
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rheumatoid arthritis signaling protein reverses Alzheimer's disease in mouse model
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent ... Fine, an app invention that can help people during emergencies. , "The worldwide ... CEO and Creative Director of World Patent Marketing. "Currently, there are about 97,000 ...
(Date:7/30/2015)... , ... July 30, 2015 , ... The connection between a healthy head of hair ... The loss of a full head of hair can have a devastating impact on the ... is perceived in the work place, the consequences of hair loss are not to be ...
(Date:7/30/2015)... ... 2015 , ... Mullin/Ashley Associates, Inc. , an integrated ... the Service Industry Advertising Awards 12th annual national competition. , The awards ... University of Maryland Shore Regional Health. , A Gold Award was won by ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Orange, Riverside, Los Angeles, and San Bernardino counties, today announced that Dr. Michael ... Care Administrator. Dr. Demoratz is a strong proponent of early access to palliative ...
(Date:7/30/2015)... ... July 30, 2015 , ... OncLive®’s extensive ... UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects ... editorial and marketing groups will help spread the news about the center’s leading-edge ...
Breaking Medicine News(10 mins):Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4
... physicians identified six cases of accidental ingestion of wire ... paper calls attention to the need for the public and ... published in the American Journal of Roentgenology and ... Grand, M.D., a radiologist in the diagnostic imaging department at ...
... 28 (HealthDay News) -- Tourists over age 65 who visit malaria-infested ... disease than those ages 18 to 35, a new study says. ... 25,000 U.K. patients also found that the malaria death rate is ... The risk of dying from malaria, an infection carried by mosquitoes, ...
... , WEDNESDAY, March 28 (HealthDay News) -- A drink or ... in the two decades following a heart attack, a new study ... European Heart Journal , included more than 1,800 American men ... were followed for up to 20 years. During that time, 468 ...
... treated with intensity modulated radiation therapy (IMRT) instead of ... of acute or chronic toxicities, according to a study ... the official clinical practice journal of the American Society ... to determine the most effective breast cancer treatment that ...
... Salamon HealthDay Reporter , MONDAY, March 26 (HealthDay ... new study suggests. Those who spend 11 or more hours ... over the next three years regardless of how physically active ... more than 222,000 people aged 45 and older, Australian researchers ...
... 27 (HealthDay News) -- Women with ovarian cancer who ... have annual incomes of less than $35,000 are more ... Researchers found these racial and socioeconomic disparities in ... of surviving for five years after their cancer diagnosis. ...
Cached Medicine News:Health News:Rhode Island Hospital study identifies the danger of grill brushes 2Health News:Older Travelers at Much Higher Risk of Dying From Malaria 2Health News:Moderate Drinking Might Help Men Live Longer After Heart Attack 2Health News:IMRT reduces risk of side effects in breast cancer patients 2Health News:Too Much Sitting Can Kill You, Study Suggests 2Health News:Too Much Sitting Can Kill You, Study Suggests 3Health News:Black Women, Uninsured Get Worse Ovarian Cancer Care: Study 2
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... , July 30, 2015 Takeda ... the study to fulfill the post-marketing commitment and ... Pan European Multi-Database Bladder Cancer Risk Characterization ... matched cohort study, conducted in four European countries, ... with up to 10 years of follow-up. Findings ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Oct. 28 Horror stories related to medical equipment for ... thousands, even millions of dollars are wasted, and delays in ... www.ecri.org ), an independent nonprofit that researches the best ... equipment issues and 6 best practices to ensure a better ...
... Pharmaceuticals, Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical ... sales volumes of the Levulan® Kerastick®, an integral ... platform, surpassed one million units. , "The achievement ... U.S. and abroad continue to embrace Levulan PDT ...
Cached Medicine Technology:Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 2Is Poor Medical Equipment Planning Costing your Healthcare Project Wasted Dollars and Delays? ECRI Institute outlines best practices to ensure better outcomes 3DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R) Kerastick(R) Sales Units 2
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... Advia Centaur delivers a new level of ... to integrate with any laboratory automation system. ... supplies. It is the only immunoassay system ... load samples; system runs without any additional ...
... fully automated, random access ... 50 assays available worldwide. ... marker, therapeutic drug, serology, ... can be performed on ...
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Medicine Products: